Drug application
NAPROXEN SODIUM (NAPROXEN SODIUM)
Drugs@FDA ANDA 207612 · NOVELGENIX THERAPS
Key facts
| Drug name | NAPROXEN SODIUM |
|---|---|
| Active ingredients | NAPROXEN SODIUM |
| Application type | ANDA |
| Application number | 207612 |
| Company | NOVELGENIX THERAPS |
| Dosage forms | TABLET, ORAL |
| Strength | 220MG |
| Marketing status | Discontinued |
| Reference listed drug | No |
| Latest submission status date | Nov 16, 2018 |
At a glance
- 1–9 Submissions
- None Label versions
- 1–9 Products
- None Therapeutic equivalents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.